Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.
Raaka G KumbhakarMoni NeradilekRuanne V BarnabasJenell StewartHelen C Stankiewicz KaritaRaphael J LandovitzPatricia J KissingerKeith R JeromeMichael K Paasche-OrlowAnna BershteynHelen Y ChuKathleen M NeuzilAlexander L GreningerAlfred LukAnna WaldElizabeth R BrownChristine JohnstonPublished in: Journal of medical virology (2022)
Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated the time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance.